Paclitaxel Treatment Options in Columbus, OH

A collection of 315 research studies where Paclitaxel is the interventional treatment. These studies are located in the Columbus, OH. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

NCT02501954

Completed

To determine if treatment with cisplatin and radiation followed by carbo and taxol reduces the rate of recurrence when compared to sandwich therapy.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

07/22/2024

Locations: The Ohio State University, Columbus, Ohio

Conditions: Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer

Learn More ›

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

NCT05624918

Recruiting

This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8 and 15), and TTFields (worn every day for at least 18 hours). Following the initial 3 cycles of gemcitabine/nab-paclitaxel/TTFields treatment, patients will undergo restaging by CT or MRI. Patients with stable disease or better will undergo surgery for resection within 8 weeks following completion of initial chemotherapy although enrolling sites ar... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/05/2024

Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Conditions: Pancreatic Adenocarcinoma, Resectable Pancreatic Cancer

Learn More ›

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

NCT02883062

Completed

This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tum... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

07/02/2024

Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Conditions: Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma

Learn More ›

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

NCT05092360

Active Not Recruiting

This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/27/2024

Locations: University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio +2 locations

Conditions: Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Learn More ›

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT04001829

Active Not Recruiting

This phase II trial studies whether a prior germline predictor of taxane-induced peripheral neuropathy (TIPN) can help identify a subgroup of patients who are at higher risk of chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer. The study also investigates whether docetaxel maybe work better than paclitaxel with regard to TIPN rate/severity and dose reductions.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/12/2024

Locations: Cleveland Clinic Akron General, Akron, Ohio +39 locations

Cleveland Clinic Akron General, Akron, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Geauga Hospital, Chardon, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Dublin Methodist Hospital, Dublin, Ohio

Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio

Mount Carmel Grove City Hospital, Grove City, Ohio

Fairfield Medical Center, Lancaster, Ohio

Saint Rita's Medical Center, Lima, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

OhioHealth Marion General Hospital, Marion, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

University Hospitals Parma Medical Center, Parma, Ohio

Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

University Hospitals Portage Medical Center, Ravenna, Ohio

UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio

Saint Vincent Mercy Medical Center, Toledo, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

University Hospitals Sharon Health Center, Wadsworth, Ohio

Saint Ann's Hospital, Westerville, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8

Learn More ›

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

NCT02488967

Active Not Recruiting

This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whethe... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/31/2024

Locations: Cleveland Clinic Akron General, Akron, Ohio +94 locations

Cleveland Clinic Akron General, Akron, Ohio

Cleveland Clinic Cancer Center Beachwood, Beachwood, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Indu and Raj Soin Medical Center, Beavercreek, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Mercy Medical Center, Canton, Ohio

Aultman Health Foundation, Canton, Ohio

Dayton Physicians LLC-Miami Valley South, Centerville, Ohio

Miami Valley Hospital South, Centerville, Ohio

Geauga Hospital, Chardon, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio

Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio

The Christ Hospital, Cincinnati, Ohio

University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Oncology Hematology Care Inc - Anderson, Cincinnati, Ohio

Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Good Samaritan Hospital - Dayton, Dayton, Ohio

Miami Valley Hospital, Dayton, Ohio

Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Delaware Radiation Oncology, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Dublin Methodist Hospital, Dublin, Ohio

Mercy Cancer Center-Elyria, Elyria, Ohio

Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio

Armes Family Cancer Center, Findlay, Ohio

Blanchard Valley Hospital, Findlay, Ohio

Orion Cancer Care, Findlay, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Dayton Physicians LLC-Atrium, Franklin, Ohio

Dayton Physicians LLC-Wayne, Greenville, Ohio

Wayne Hospital, Greenville, Ohio

Cleveland Clinic Cancer Center Independence, Independence, Ohio

Greater Dayton Cancer Center, Kettering, Ohio

First Dayton Cancer Care, Kettering, Ohio

Kettering Medical Center, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

OhioHealth Marion General Hospital, Marion, Ohio

Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Landerbrook Health Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

Dayton Physicians LLC-Signal Point, Middletown, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

Saint Charles Hospital, Oregon, Ohio

University Hospitals Parma Medical Center, Parma, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

University Hospitals Portage Medical Center, Ravenna, Ohio

North Coast Cancer Care, Sandusky, Ohio

UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio

Dayton Physicians LLC-Wilson, Sidney, Ohio

Springfield Regional Cancer Center, Springfield, Ohio

Springfield Regional Medical Center, Springfield, Ohio

Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio

ProMedica Flower Hospital, Sylvania, Ohio

The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio

University of Toledo, Toledo, Ohio

Mercy Saint Anne Hospital, Toledo, Ohio

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

Dayton Physicians LLC-Upper Valley, Troy, Ohio

Upper Valley Medical Center, Troy, Ohio

University Hospitals Sharon Health Center, Wadsworth, Ohio

South Pointe Hospital, Warrensville Heights, Ohio

University Pointe, West Chester, Ohio

Saint Ann's Hospital, Westerville, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

UHHS-Westlake Medical Center, Westlake, Ohio

Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma

Learn More ›

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

NCT00070564

Active Not Recruiting

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer. PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how w... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/11/2024

Locations: McDowell Cancer Center at Akron General Medical Center, Akron, Ohio +60 locations

McDowell Cancer Center at Akron General Medical Center, Akron, Ohio

Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio

Barberton Citizens Hospital, Barberton, Ohio

Cleveland Clinic Beachwood Family Health and Surgery Center, Beachwood, Ohio

Mary Rutan Hospital, Bellefontaine, Ohio

Wood County Oncology Center, Bowling Green, Ohio

Mercy Cancer Center at Mercy Medical Center, Canton, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Good Samaritan Hospital Cancer Treatment Center, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

Case Comprehensive Cancer Center, Cleveland, Ohio

Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Riverside Methodist Hospital Cancer Care, Columbus, Ohio

CCOP - Columbus, Columbus, Ohio

Grant Medical Center Cancer Care, Columbus, Ohio

Mount Carmel Health - West Hospital, Columbus, Ohio

Doctors Hospital at Ohio Health, Columbus, Ohio

Grandview Hospital, Dayton, Ohio

Good Samaritan Hospital, Dayton, Ohio

David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio

Samaritan North Cancer Care Center, Dayton, Ohio

CCOP - Dayton, Dayton, Ohio

Grady Memorial Hospital, Delaware, Ohio

Community Cancer Center, Elyria, Ohio

Hematology Oncology Center, Elyria, Ohio

Blanchard Valley Medical Associates, Findlay, Ohio

Middletown Regional Hospital, Franklin, Ohio

Wayne Hospital, Greenville, Ohio

Cleveland Clinic Cancer Center, Independence, Ohio

Charles F. Kettering Memorial Hospital, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

St. Rita's Medical Center, Lima, Ohio

Lima Memorial Hospital, Lima, Ohio

MedCentral - Mansfield Hospital, Mansfield, Ohio

Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio

Northwest Ohio Oncology Center, Maumee, Ohio

Hillcrest Cancer Center at Hillcrest Hospital, Mayfield Heights, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio

Fisher-Titus Medical Center, Norwalk, Ohio

St. Charles Mercy Hospital, Oregon, Ohio

Toledo Clinic - Oregon, Oregon, Ohio

Parma Community General Hospital, Parma, Ohio

North Coast Cancer Care, Incorporated, Sandusky, Ohio

Community Hospital of Springfield and Clark County, Springfield, Ohio

Cleveland Clinic Foundation - Strongsville, Strongsville, Ohio

Flower Hospital Cancer Center, Sylvania, Ohio

Mercy Hospital of Tiffin, Tiffin, Ohio

Toledo Hospital, Toledo, Ohio

St. Vincent Mercy Medical Center, Toledo, Ohio

Medical University of Ohio Cancer Center, Toledo, Ohio

CCOP - Toledo Community Hospital, Toledo, Ohio

St. Anne Mercy Hospital, Toledo, Ohio

Toledo Clinic, Incorporated - Main Clinic, Toledo, Ohio

UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio

Fulton County Health Center, Wauseon, Ohio

Mount Carmel St. Ann's Cancer Center, Westerville, Ohio

Cleveland Clinic - Wooster, Wooster, Ohio

Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio

Genesis - Good Samaritan Hospital, Zanesville, Ohio

Conditions: Breast Cancer

Learn More ›

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

NCT03940196

Completed

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer . The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/28/2024

Locations: Miami Valley Hospital South, Centerville, Ohio +1 locations

Conditions: Ovarian Cancer

Learn More ›

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT03840902

Terminated

The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/12/2024

Locations: The James Cancer Hospital and Solove Research Institute, Columbus, Ohio

Conditions: Non-small Cell Lung Cancer

Learn More ›

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117

Active Not Recruiting

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

12/15/2023

Locations: SCC at UH Geauga Medical Center, Chardon, Ohio +8 locations

Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms

Learn More ›

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

NCT01325441

Completed

This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/13/2023

Locations: Ohio State University Wexner Medical Center, Columbus, Ohio

Conditions: Cancer

Learn More ›

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

NCT02178956

Completed

The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

11/13/2023

Locations: Ohio State University Medical Center, Columbus, Ohio

Conditions: Gastric Cancer, Gastroesophageal Junction Cancer

Learn More ›

Browse Paclitaxel Treatment Options in Other Ohio Cities

Paclitaxel treatment options in Cleveland

Paclitaxel treatment options in Cincinnati